ANA antinuclear antibody
Selected indexed studies
- Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. (Nat Rev Rheumatol, 2020) [PMID:33154583]
- Antinuclear Antibody Tests. (Clin Lab Med, 2019) [PMID:31668266]
- Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy. (Clin Exp Immunol, 2023) [PMID:36966354]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. (2020) pubmed
- Antinuclear Antibody Tests. (2019) pubmed
- Antinuclear antibody (ANA) status predicts immune-related adverse events in liver cancer patients undergoing anti-PD-1 therapy. (2023) pubmed
- Antinuclear Antibodies in Non-Rheumatic Diseases. (2025) pubmed
- Antinuclear antibody (ANA) monitoring in drug-induced lupus erythematosus (DILE). (2021) pubmed
- Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP. (2023) pubmed
- Mitigating overuse of antinuclear antibody (ANA) testing through educational intervention: a study in internal medicine and neurology departments. (2024) pubmed
- Autoimmune hepatitis. (2014) pubmed
- Historical Perspective on Antinuclear Antibody Testing. (2025) pubmed
- Significance of antinuclear antibody (ANA) immunofluorescent patterns and titers in systemic lupus erythematosus nephritis. (1988) pubmed